reltecimod

Reltecimod is a synthetic immunomodulatory peptide developed for the treatment of suspected organ dysfunction or failure in patients with necrotizing soft tissue infection (NSTI). It acts as an antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor, thereby modulating the acute inflammatory response that leads to organ dysfunction or failure in NSTI. Reltecimod is administered intravenously and has been evaluated in phase 3 clinical trials, where it demonstrated clinically meaningful effects on resolution of organ dysfunction compared to placebo. The drug was developed by Atox Bio and has received Fast Track and Orphan Drug designations from the FDA for this indication[1][5][6][7].

Other names

reltecimod sodiumD-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-aspartyl-D-alanine